Evidence map›Paper›PMID 31052369›Full record

ArticlePharmaceutics2019

Exploring Light-Sensitive Nanocarriers for Simultaneous Triggered Antibiotic Release and Disruption of Biofilms Upon Generation of Laser-Induced Vapor Nanobubbles.

Eline Teirlinck, Alexandre Barras, Jing Liu, Juan C Fraire, Tatu Lajunen, Ranhua Xiong, Katrien Forier, Chengnan Li, Arto Urtti, Rabah Boukherroub and 4 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 4 countries.

Eline TeirlinckLaboratory of General Biochemistry and Physical Pharmacy, University of Ghent, 9000 Ghent, Belgium. Eline.Teirlinck@UGent.be.ORCID 0000-0002-6518-3835
Alexandre BarrasUniv. Lille, CNRS, Centrale Lille, ISEN, Univ. Valenciennes, UMR 8520-IEMN, 59000 Lille, France. alexandre.barras@univ-lille.fr.ORCID 0000-0003-2821-7079
Jing LiuLaboratory of General Biochemistry and Physical Pharmacy, University of Ghent, 9000 Ghent, Belgium. jingli.Liu@UGent.be.
Juan C FraireLaboratory of General Biochemistry and Physical Pharmacy, University of Ghent, 9000 Ghent, Belgium. Juan.Fraire@UGent.be.ORCID 0000-0002-4887-2161
Tatu LajunenDrug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00790 Helsinki, Finland. tatu.lajunen@helsinki.fi.ORCID 0000-0001-6234-9193
Ranhua XiongLaboratory of General Biochemistry and Physical Pharmacy, University of Ghent, 9000 Ghent, Belgium. Ranhua.Xiong@UGent.be.
Katrien ForierLaboratory of General Biochemistry and Physical Pharmacy, University of Ghent, 9000 Ghent, Belgium. Katrien.Forier@UGent.be.
Chengnan LiUniv. Lille, CNRS, Centrale Lille, ISEN, Univ. Valenciennes, UMR 8520-IEMN, 59000 Lille, France. neu_lcn@163.com.
Arto UrttiDrug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00790 Helsinki, Finland. arto.urtti@helsinki.fi.
Rabah BoukherroubUniv. Lille, CNRS, Centrale Lille, ISEN, Univ. Valenciennes, UMR 8520-IEMN, 59000 Lille, France. rabah.boukherroub@univ-lille.fr.
Sabine SzuneritsUniv. Lille, CNRS, Centrale Lille, ISEN, Univ. Valenciennes, UMR 8520-IEMN, 59000 Lille, France. Sabine.Szunerits@univ-lille1.fr.ORCID 0000-0002-1567-4943
Stefaan C De SmedtLaboratory of General Biochemistry and Physical Pharmacy, University of Ghent, 9000 Ghent, Belgium. Stefaan.Desmedt@UGent.be.
Tom CoenyeLaboratory of Pharmaceutical Microbiology, University of Ghent, 9000 Ghent, Belgium. Tom.Coenye@UGent.be.
Kevin BraeckmansLaboratory of General Biochemistry and Physical Pharmacy, University of Ghent, 9000 Ghent, Belgium. Kevin.Braeckmans@UGent.be.ORCID 0000-0002-7993-6295
Ghent University · BECentre National de la Recherche Scientifique · FRUniversity of Helsinki · FI

Funding

Agentschap voor Innovatie door Wetenschap en Technologie 141135European Research Council 648124Fonds Wetenschappelijk Onderzoek 1500418NLight Activated Drug Delivery System (LADDS) project 4208/31/2015University Ghent Special Research Fund/Concerted Research Actions 01G02215
6 · The paper itself

Abstract

Impaired penetration of antibiotics through bacterial biofilms is one of the reasons for failure of antimicrobial therapy. Hindered drug diffusion is caused on the one hand by interactions with the sticky biofilm matrix and on the other hand by the fact that bacterial cells are organized in densely packed clusters of cells. Binding interactions with the biofilm matrix can be avoided by encapsulating the antibiotics into nanocarriers, while interfering with the integrity of the dense cell clusters can enhance drug transport deep into the biofilm. Vapor nanobubbles (VNB), generated from laser irradiated nanoparticles, are a recently reported effective way to loosen up the biofilm structure in order to enhance drug transport and efficacy. In the present study, we explored if the disruptive force of VNB can be used simultaneously to interfere with the biofilm structure and trigger antibiotic release from light-responsive nanocarriers. The antibiotic tobramycin was incorporated in two types of light-responsive nanocarriers-liposomes functionalized with gold nanoparticles (Lip-AuNP) and graphene quantum dots (GQD)-and their efficacy was evaluated on

Indexed as

biofilmsdiffusion barriergold nanoparticlesgraphene quantum dotslaser treatmentliposomestriggered releasevapor nanobubbles

Identifiers

PMID31052369
PMCPMC6571820
OpenAlexW2942947610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.